Atlas Trials

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Clinical trial NCT04925479 · RECRUITING

Trial details

NCT number
NCT04925479
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Myeloid Leukemia, Philadelphia Positive
Start date
2021-12-27
Primary completion
2027-09-21
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.